Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
5 reports, 3 independent
Updated Sep 15
Gone quiet
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Company listed on Nasdaq and received Fast Track designation from the FDA.1 source
Company listed on Nasdaq; FDA hearing scheduled at White Oak Campus.1 source
Iovance Biotherapeutics received Fast Track designation from the FDA.1 source
Keep exploring
The entities involved
-
Iovance Biotherapeutics
American biopharmaceutical startup
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
- FDA
Related events
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Connect Biopharma listed its stock on the Nasdaq exchange on August 1, 2026.
- Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Evelo Biosciences listed its stock on the Nasdaq exchange on August 1, 2026.